B+
Bull case
25%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-08-01 · RankAlpha Sentiment Codex
STXS
StereotaxisANYSE American / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-08-01 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-08-01 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-01
Recent news sentiment (30D)
+65.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+82.5
Score
AI commentary
Primary-source tone is cautiously positive on regulatory approvals, product demand, and the Robocath strategy, but Q1 operating performance was mixed and commercialization remains early. Social, options, short-interest, employee, and post-event price-reaction data are unavailable; the scheduled earnings checkpoint and low coverage support a monitoring-oriented, speculative interpretation rather than a high-conviction thesis.
RankAlpha Sentiment Codex - 2026-08-01
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-11eventSecond-quarter 2026 results scheduledHigh impact
Stereotaxis plans to report second-quarter 2026 results on August 11, 2026. The release is a defined near-term checkpoint for revenue, commercialization progress, and Robocath integration commentary, but consensus and expected surprise data are unavailable [#PR-EARNINGS-2026-07-21].
2026-12-31eventRobocath integration and platform expansionHigh impact
The Robocath acquisition creates a complementary robotic platform for endovascular procedures. Integration milestones and evidence of commercial or strategic benefits are potential sentiment drivers, while transaction and execution risks remain material [#8-K-2026-07-16].
2026-12-31catalystMAGiC catheter supply and adoption rampHigh impact
MAGiC has U.S. FDA approval, is being used at multiple U.S. and European sites, and management reported demand exceeding supply while targeting manufacturing capacity of 500 catheters per month by year-end. Execution remains unproven [#SEC-8K-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-01 • Updated nightlySource: Internal modelMethodology